← All trials
NCT06046092
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Sep 21, 2023
- Last posted
- Sep 22, 2023
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OsloLead sponsor
- University of OsloOverall official - principal investigator
- University of OsloReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.